Premier Anti-Aging Co., Ltd. (4934) AI Stock Analysis

• Market Cap: ¥5.41B
• Dividend Yield: N/A
• Average Volume (3M): 11.01K
• Price to Earnings (P/E): 42.4
• Beta (1Y): 1.03
• Revenue Growth: -19.42%
• EPS Growth: N/A
• Country: JP
• Employees: 229
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 4.26
• Shares Outstanding: 8,720,534
• 10 Day Avg. Volume: 8,960
• 30 Day Avg. Volume: 11,006
• PEG Ratio: -0.12
• Price to Book (P/B): 1.14
• Price to Sales (P/S): 0.47
• P/FCF Ratio: 5.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 49.3
• Revenue Forecast (FY): ¥15.00B

• Rating: 52 Neutral
• Price Target: ¥626.00 ▼(-10.83% Downside)
• Action: Reiterated Date: 10/03/25
• Date: Action: Reiterated 10/03/25

The overall stock score is primarily impacted by the company's financial performance, which shows strengths in gross profit margin and balance sheet stability but is hindered by declining revenues and low profitability. Technical analysis indicates bearish momentum, further weighing down the score. Valuation is a relative strength, with a reasonable P/E ratio, but the lack of a dividend yield is a drawback.

Positive Factors

High gross profit margin

A 76.65% gross margin indicates durable product-level economics and meaningful pricing power in its anti-aging portfolio. Such a high gross margin provides a lasting cushion to absorb SG&A or R&D, supports reinvestment, and helps preserve profitability despite revenue variability.

Conservative leverage and solid capital structure

Low leverage (D/E 0.17) and a healthy equity ratio give the company durable financial flexibility. This conservative balance sheet reduces refinancing and solvency risk, enabling longer-term investment in product development, marketing, or M&A without excessive funding stress.

Strong free cash flow conversion

Near‑one-to-one free cash flow conversion shows the business effectively turns accounting profits into cash. Improved FCF supports self‑funded operations, capacity upgrades or product investment, lowering reliance on external capital and improving durability through cycles.

Negative Factors

Declining revenue trend

A persistent top-line decline signals weakening demand, market share loss, or distribution challenges. Structurally lower revenue reduces operating leverage, makes fixed-cost absorption harder, and constrains long‑term investment capacity and margin expansion unless growth stabilizes.

Low net and operating margins

Very low net and operating margins limit the firm's ability to build retained earnings and reinvest in growth. This thin profitability leaves less room to weather cost inflation or invest in marketing/R&D, reducing long‑term competitiveness compared with higher‑margin peers.

Moderate operating cash conversion vs. earnings

OCF equal to roughly half of reported net income suggests earnings quality or working capital volatility issues. If operating cash fails to consistently match earnings, the company may face constraints funding capex or growth internally, increasing reliance on external funding in stress periods.

Premier Anti-Aging Co., Ltd. Business Overview & Revenue Model

Company Description

Premier Anti-Aging Co., Ltd. engages in the planning, development, import/export, mail order, wholesale, and retail business of cosmetics and health foods. The company offers its cosmetic products under the DUO and CANADEL brands. It is also involved on the information provision and consulting services related to anti-aging, beauty, and health; research on management and beauty of beauty clinics, etc.; and marketing research and collection and analysis of various information. The company was founded in 2009 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Revenue is generated primarily through the sale of the company’s anti-aging-related offerings (e.g., products and/or services marketed under its brand). A more detailed breakdown of specific revenue streams (such as channel mix, product category composition, recurring vs. one-time revenue, or named major partnerships) is null based on the information available here.

Premier Anti-Aging Co., Ltd. Financial Statement Overview

Summary

Premier Anti-Aging Co., Ltd. shows a strong gross profit margin and a stable balance sheet with low leverage. However, declining revenues and low net profit margins are concerning. Cash flow has improved, but operational efficiency needs enhancement to boost profitability.

Income Statement

Premier Anti-Aging Co., Ltd. has experienced declining revenue over the past few years, with a negative revenue growth rate of -7.23% in the most recent year. The gross profit margin remains strong at 76.65%, indicating efficient production processes. However, the net profit margin is low at 2.91%, reflecting challenges in controlling costs or increasing sales. The EBIT and EBITDA margins are also low, suggesting limited operational efficiency and profitability.

Balance Sheet

The company's balance sheet shows a stable debt-to-equity ratio of 0.17, indicating conservative leverage. The return on equity is moderate at 7.13%, suggesting reasonable profitability from shareholders' investments. The equity ratio is healthy, reflecting a solid capital structure with a good proportion of equity financing.

Cash Flow

Cash flow analysis reveals a significant improvement in free cash flow, with a growth rate of 'Infinity' due to a previous negative base. The operating cash flow to net income ratio is 0.49, indicating moderate cash generation relative to net income. The free cash flow to net income ratio is high at 0.98, suggesting effective conversion of profits into cash.

Breakdown	Jul 2025	Jul 2024	Jul 2023	Jul 2022	Jul 2021
Income Statement
Total Revenue	16.16B	20.36B	26.40B	33.91B	32.81B
Gross Profit	12.39B	16.10B	19.24B	26.63B	26.43B
EBITDA	916.00M	390.00M	-423.24M	2.50B	4.72B
Net Income	471.00M	-1.48B	-733.97M	1.42B	2.79B
Balance Sheet
Total Assets	10.14B	11.05B	12.18B	12.30B	13.07B
Cash, Cash Equivalents and Short-Term Investments	4.66B	4.76B	4.67B	2.97B	6.06B
Total Debt	1.11B	2.44B	2.26B	1.41B	911.41M
Total Liabilities	3.53B	4.92B	4.57B	3.95B	6.17B
Stockholders Equity	6.61B	6.12B	7.61B	8.35B	6.90B
Cash Flow
Free Cash Flow	1.44B	-204.00M	2.40B	-3.35B	2.75B
Operating Cash Flow	1.47B	425.00M	2.42B	-3.32B	2.75B
Investing Cash Flow	-229.00M	-540.00M	-900.97M	-297.68M	-180.83M
Financing Cash Flow	-1.34B	183.00M	179.77M	501.62M	1.58B

Premier Anti-Aging Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 702.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4934, the sentiment is Negative. The current price of 702 is below the 20-day moving average (MA) of 726.85, below the 50-day MA of 719.40, and below the 200-day MA of 785.89, indicating a bearish trend. The MACD of -22.51 indicates Positive momentum. The RSI at 32.43 is Neutral, neither overbought nor oversold. The STOCH value of 3.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4934.

Premier Anti-Aging Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4933	71 Outperform	¥19.16B	33.88	―	0.91%	13.12%	27.53%
4918	68 Neutral	¥2.19B	-3.04	―	―	12.96%	―
4925	63 Neutral	¥6.81B	12.52	―	2.38%	-0.79%	―
4936	63 Neutral	¥7.98B	-49.92	―	2.65%	11.87%	-31.02%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
4926	58 Neutral	¥5.67B	-33.12	―	1.68%	8.46%	―
4934	52 Neutral	¥5.41B	42.42	―	―	-19.42%	―

Premier Anti-Aging Co., Ltd. Corporate Events

Premier Anti-Aging Outlines FY2026 Q2 Results and Outlook

Premier Anti-Aging Co., Ltd., a TSE Growth Market-listed beauty and wellness company specializing in anti-aging products, has released its FY2026 second-quarter results briefing materials. The documents outline performance in its core Anti-Aging Business and its Recovery Business segments, as well as sustainability initiatives and an earnings forecast for FY2026, signaling management priorities and operational direction for the coming periods.

The most recent analyst rating on (JP:4934) stock is a Hold with a Yen854.00 price target. To see the full list of analyst forecasts on Premier Anti-Aging Co., Ltd. stock, see the JP:4934 Stock Forecast page.

Premier Anti-Aging Beats Profit Forecasts Despite Weaker Sales and Keeps Full-Year Outlook

Premier Anti-Aging reported interim consolidated net sales of ¥7.34 billion for the six months to Jan. 31, 2026, falling short of its ¥8.0 billion forecast as mail order anti-aging sales and the Venex recovery business underperformed amid slow new customer acquisition and intensifying online competition. However, operating profit surged to ¥626 million versus a ¥150 million forecast, and profit attributable to owners of parent jumped to ¥445 million, as lower-than-planned advertising spend in the anti-aging segment and deeper cost-cutting in personnel and outsourcing costs more than offset weaker revenue.

Management signaled a challenging environment ahead for mail order and wholesale sales, particularly in the Chinese market, and for the Venex recovery business facing stronger e-commerce rivals, but chose to keep full-year earnings forecasts unchanged. From the third quarter, the company plans to ramp up advertising and promotional investment across both anti-aging and recovery brands, including digital and influencer tie-ups, indicating a shift from short-term cost restraint toward growth-oriented marketing while monitoring whether competitive and macro pressures warrant future forecast revisions.

The most recent analyst rating on (JP:4934) stock is a Hold with a Yen854.00 price target. To see the full list of analyst forecasts on Premier Anti-Aging Co., Ltd. stock, see the JP:4934 Stock Forecast page.

Premier Anti-Aging Posts Lower First-Half Earnings but Maintains Full-Year Outlook

Premier Anti-Aging reported a 13.9% year-on-year decline in net sales to ¥7.34 billion for the first half of the fiscal year ending July 31, 2026, with operating profit down 36.0% to ¥626 million and profit attributable to owners of parent falling 23.4% to ¥445 million. Despite profit pressure, the company’s equity ratio improved to 67.0% and shareholders’ equity increased, indicating a relatively solid balance sheet amid weaker earnings.

The company maintained its full-year forecast, projecting modest net sales growth of 2.1% to ¥16.5 billion but a sharp drop in operating profit of 51.4%, signaling expectations of continued margin compression. It also kept its no-dividend policy for the current fiscal year, suggesting a focus on preserving capital and financial flexibility, which may temper income expectations for shareholders while supporting longer-term operational resilience.

The most recent analyst rating on (JP:4934) stock is a Hold with a Yen854.00 price target. To see the full list of analyst forecasts on Premier Anti-Aging Co., Ltd. stock, see the JP:4934 Stock Forecast page.